The AI-driven platform identifies cell cycle deregulation and tumor immune microenvironment dynamics from biopsy images.

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...

Although the readout was only from four multiple myeloma patients, attendees at the meeting wondered at how far the CAR T-cell therapy field has come.

Once the exchange agreements close, Sarepta will have $893.4 million in debt due in 2030 following previous refinancing it announced in August.

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

At SABCS, Mayo Clinic researchers reported PRS data was more likely to change the risk categories of people with variants in moderate risk penetrance genes.